LOXL3 and neoplasm: To explore the treatment strategy of utilizing low-dose Oxaliplatin to dampen the LOXL3–DHODH axis, we first performed subcutaneous transplantation of tumor cells expressing the S704A mutant, or of control tumor cells: there was no significant difference in solid-tumor formation (Fig. 6a).